The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Wang, Xianyun ^a   Zhang, Jun ^a   Zhang, Fan ^a   Li, Jing ^a   Li, Yaqi ^a   Tan, Zirui ^a   Hu, Jie ^a   Qi, Yixin ^a   Li, Quanhai ^a   Yan, Baoyong ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; STEM CELL FACTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGINA PECTORIS; ANGIOGENESIS; BONE MARROW DERIVED MONONUCLEAR CELL; BONE MARROW DERIVED MONONUCLEAR CELL TRANSPLANTATION; CARDIAC DERIVED STEM CELL; CARDIAC DERIVED STEM CELL TRANSPLANTATION; CARDIOSPHERE DERIVED AUTOLOGOUS STEM CELL; CARDIOSPHERE DERIVED AUTOLOGOUS STEM CELL TRANSPLANTATION; CD133+ CELL; CD133+ CELL ENGRAFTING THERAPY; CD34+ CELL; CD34+ CELL THERAPY; CELL ACTIVITY; CELL COUNT; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; ENDOTHELIAL PROGENITOR CELL; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATOPOIETIC STEM CELL; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROENVIRONMENT; MORTALITY; MYOBLAST; NONHUMAN; PATIENT SAFETY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKELETAL MYOBLAST TRANSPLANTATION; STEM CELL; STEM CELL TRANSPLANTATION; STENT THROMBOSIS; TERATOMA;

EID: 84935908146     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/135023     Document Type: Review

References (120)

1. A. S. Go, D. Mozaffarian, V. L. Roger et al., "Heart disease and stroke statistics-2014 update: a report from the American Heart Association," Circulation, vol. 129, no. 3, pp. e28-e292, 2014.
2. R. J. Henning, "Stem cells in cardiac repair," Future Cardiology, vol. 7, no. 1, pp. 99-117, 2011.
3. A. P. Beltrami, L. Barlucchi, D. Torella et al., "Adult cardiac stem cells are multipotent and support myocardial regeneration," Cell, vol. 114, no. 6, pp. 763-776, 2003.
4. T. Hosoda, "C-kit-positive cardiac stem cells and myocardial regeneration," American Journal of Cardiovascular Disease, vol. 2, no. 1, pp. 58-67, 2012.
5. K. Urbanek, D. Torella, F. Sheikh et al., "Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8692-8697, 2005.
6. R. Zamilpa, "Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: repair and regeneration," World Journal of Cardiology, vol. 6, no. 7, pp. 610-620, 2014.
7. D. Pangonyte, E. Stalioraityte, R. Ziuraitiene, D. Kazlauskaite, J. Palubinskiene, and I. Balnyte, "Cardiomyocyte remodeling in ischemic heart disease," Medicina (Kaunas), vol. 44, no. 11, pp. 848-854, 2008.
8. D. Pangonyte, E. Stalioraityte, D. Kazlauskaite, R. Ziuraitiene, Z. Stanioniene, and S. Kerpauskiene, "Changes of heart geometry in patients with ischemic heart disease," Medicina, vol. 44, no. 1, pp. 8-14, 2008.
9. R. E. Michler, "Stem cell therapy for heart failure," Methodist DeBakey Cardiovascular Journal, vol. 9, no. 4, pp. 187-194, 2013.
10. M. Gnecchi, P. Danieli, and E. Cervio, "Mesenchymal stem cell therapy for heart disease," Vascular Pharmacology, vol. 57, no. 1, pp. 48-55, 2012.
11. M. A. Laflamme and C. E. Murry, "Heart regeneration," Nature, vol. 473, no. 7347, pp. 326-335, 2011.
12. V. F. M. Segers and R. T. Lee, "Stem-cell therapy for cardiac disease," Nature, vol. 451, no. 7181, pp. 937-942, 2008.
13. J. Tongers, D. W. Losordo, and U. Landmesser, "Stemand progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges," European Heart Journal, vol. 32, no. 10, pp. 1197-1206, 2011.
14. B. Nadal-Ginard, J. Kajstura, A. Leri, and P. Anversa, "Myocyte death, growth, and regeneration in cardiac hypertrophy and failure," Circulation Research, vol. 92, no. 2, pp. 139-150, 2003.
15. K. Urbanek, D. Cesselli, M. Rota et al., "Stem cell niches in the adult mouse heart," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 24, pp. 9226-9231, 2006.
16. A. A. Matar and J. J. Chong, "Stem cell therapy for cardiac dysfunction," SpringerPlus, vol. 3, article 440, 2014.
17. E. Messina, L. de Angelis, G. Frati et al., "Isolation and expansion of adult cardiac stem cells from human and murine heart," Circulation Research, vol. 95, no. 9, pp. 911-921, 2004.
18. K. U. Hong and R. Bolli, "Cardiac stem cell therapy for cardiac repair," Current Treatment Options in Cardiovascular Medicine, vol. 16, no. 7, article 324, 2014.
19. S. Hu, G. Yan, W. He, Z. Liu, H. Xu, and G. Ma, "The influence of disease and age on human cardiac stemcells," Annals of Clinical Biochemistry, vol. 51, part 5, pp. 582-590, 2014.
20. M. C. Capogrossi, "Cardiac stem cells fail with aging: a new mechanism for the age-dependent decline in cardiac function," Circulation Research, vol. 94, no. 4, pp. 411-413, 2004.
21. D. H. J. Thijssen, D. Torella, M. T. E. Hopman, and G. M. Ellison, "The role of endothelial progenitor and cardiac stem cells in the cardiovascular adaptations to age and exercise," Frontiers in Bioscience, vol. 14, no. 12, pp. 4685-4702, 2009.
22. P. Anversa, M. Rota, K. Urbaneket al., "Myocardial aging: a stem cell problem," Basic Research in Cardiology, vol. 100, no. 6, pp. 482-493, 2005.
23. M. Saravanakumar and H. Devaraj, "Distribution and homing pattern of c-kit+ Sca-1+ CXCR4+ resident cardiac stem cells in neonatal, postnatal, and adult mouse heart," Cardiovascular Pathology, vol. 22, no. 4, pp. 257-263, 2013.
24. R. R. Smith, L. Barile, H. C. Cho et al., "Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens," Circulation, vol. 115, no. 7, pp. 896-908, 2007.
25. R. Bolli, A. R. Chugh, D. DAmario et al., "Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial," The Lancet, vol. 378, no. 9806, pp. 1847-1857, 2011.
26. R. R. Makkar, R. R. Smith, K. Cheng et al., "Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase trial," The Lancet, vol. 379, no. 9819, pp. 895-904, 2012.
27. K. Malliaras, R. R. Makkar, R. R. Smith et al., "Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-derived aUtologous stem CElls to reverse ventricular dysfunction)," Journal of the American College of Cardiology, vol. 63, no. 2, pp. 110-122, 2014.
28. A. R. Chugh, G. M. Beache, J. H. Loughran et al., "Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance," Circulation, vol. 126, no. 11, supplement 1, pp. S54-S64, 2012.
29. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., "Comparison of allogeneic vs autologous bonemarrow-derivedmesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial,"The Journal of theAmericanMedical Association, vol. 308, no. 22, pp. 2369-2379, 2012.
30. A. W. Heldman, D. L. DiFede, J. E. Fishman et al., "Transendocardialmesenchymal stem cells and mononuclear bonemarrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial," Journal of the American Medical Association, vol. 311, no. 1, pp. 62-73, 2014.
31. M. Hansen, S. Nyby, J. Eifer Moller et al., "Intracoronary injection of CD34+-cells in chronic ischemic heart failure: 7 years follow-up of the dancell study," Cardiology, vol. 129, no. 2, pp. 69-74, 2014.
32. J. Lee, S. Lee, Y. Youn et al., "A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction," Journal of Korean Medical Science, vol. 29, no. 1, pp. 23-31, 2014.
33. V. Y. Suncion, E. Ghersin, J. E. Fishman et al., "Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: an analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial," Circulation Research, vol. 114, no. 8, pp. 1292-1301, 2014.
34. B.-E. Strauer, M. Yousef, and C. M. Schannwell, "The acute and long-term effects of intracoronary stem cell transplantation in patients with chronic heARt failure: the STAR-heart study," European Journal of Heart Failure, vol. 12, no. 7, pp. 721-729, 2010.
35. S. Hu, S. Liu, Z. Zheng et al., "Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial," Journal of the American College of Cardiology, vol. 57, no. 24, pp. 2409-2415, 2011.
36. S. F. Rodrigo, J. van Ramshorst, S. L. Beeres et al., "Intramyocardial injection of bonemarrowmononuclear cells in chronic myocardial ischemia patients after previous placebo injection improves myocardial perfusion and anginal symptoms: an intra-patient comparison," AmericanHeart Journal, vol. 164, no. 5, pp. 771-778, 2012.
37. P. Antonitsis, K. Anastasiadis, G. Koliakos et al., "Intramyocardial implantation of autologous bonemarrow-derived stemcells combined with coronary artery bypass grafting in patients with ischemic cardiomyopathy: a pilot study," Hippokratia, vol. 16, no. 4, pp. 366-370, 2012.
38. E. C. Perin, J. T. Willerson, C. J. Pepine et al., "Effect of transendocardial delivery of autologous bonemarrowmononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial," Journal of the AmericanMedical Association, vol. 307, no. 16, pp. 1717-1726, 2012.
39. D. Surder, R. Manka, V. Lo Cicero et al., "Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function," Circulation, vol. 127, no. 19, pp. 1968-1979, 2013.
40. T. Santoso, C. W. Siu, C. Irawan et al., "Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: a randomized placebocontrolled trial (END-HF)," Journal of Cardiovascular Translational Research, vol. 7, no. 6, pp. 545-552, 2014.
41. B. Assmus, A. Rolf, S. Erbs et al., "Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction," Circulation: Heart Failure, vol. 3, no. 1, pp. 89-96, 2010.
42. D. M. Leistner, U. Fischer-Rasokat, J. Honold et al., "Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy," Clinical Research in Cardiology, vol. 100, no. 10, pp. 925-934, 2011.
43. A. R. Williams, B. Trachtenberg, D. L. Velazquez et al., "Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling," Circulation Research, vol. 108, no. 7, pp. 792-796, 2011.
44. S. Wang, J. Cui, W. Peng, and M. Lu, "Intracoronary autologous CD34+ stem cell therapy for intractable angina," Cardiology, vol. 117, no. 2, pp. 140-147, 2010.
45. D. W. Losordo, T. D. Henry, C. Davidson et al., "Intramyocardial, autologous CD34+ cell therapy for refractory angina," Circulation Research, vol. 109, no. 4, pp. 428-436, 2011.
46. G. Poglajen, M. Sever, M. Cukjati et al., "Effects of transendocardial CD34+ Cell transplantation in patients with ischemic cardiomyopathy," Circulation: Cardiovascular Interventions, vol. 7, no. 4, pp. 552-559, 2014.
47. S. Mansour, D.-C. Roy, V. Bouchard et al., "COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: Study rationale and design," Journal of Cardiovascular Translational Research, vol. 3, no. 2, pp. 153-159, 2010.
48. S. Mansour, D.-C. Roy, V. Bouchard et al., "COMPARE-AMI trial: Comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design," Journal of Cardiovascular Translational Research, vol. 3, no. 2, pp. 153-159, 2010.
49. U. Kurbonov, A. Dustov, A. Barotov et al., "Intracoronary infusion of autologous CD133+ cells in myocardial infarction and tracing by Tc99m MIBI scintigraphy of the heart areas involved in cell homing," Stem Cells International, vol. 2013, Article ID 582527, 9 pages, 2013.
50. J. Forcillo, L.-M. Stevens, S. Mansour et al., "Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot trial," Canadian Journal of Cardiology, vol. 29, no. 4, pp. 441-447, 2013.
51. A. Assmann, M. Heke, P. Kropil et al., "Laser-supported CD133+ cell therapy in patients with ischemic cardiomyopathy: initial results from a prospective phase Imulticenter trial," PLoS ONE, vol. 9, no. 7, Article ID e101449, 2014.
52. B. A. Nasseri, W. Ebell, M. Dandel et al., "Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial," European Heart Journal, vol. 35, no. 19, pp. 1263-1274, 2014.
53. T. Fujita, T. Sakaguchi, S. Miyagawa et al., "Clinical impact of combined transplantation of autologous skeletal myoblasts and bone marrow mononuclear cells in patients with severely deteriorated ischemic cardiomyopathy," Surgery Today, vol. 41, no. 8, pp. 1029-1036, 2011.
54. J. Brickwedel, H. Gulbins, and H. Reichenspurner, "Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease," Interactive Cardiovascular and Thoracic Surgery, vol. 18, no. 1, pp. 61-66, 2014.
55. S. Dimmeler and A. M. Zeiher, "Cell therapy of acute myocardial infarction: open questions," Cardiology, vol. 113, no. 3, pp. 155-160, 2009.
56. L. B. Balsam, A. J. Wagers, J. L. Christensen, T. Kofidis, I. L. Weissmann, and R. C. Robbins, "Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium," Nature, vol. 428, no. 6983, pp. 668-673, 2004.
57. S. Zhang, P. Zhang, J. Guo et al., "Enhanced cytoprotection and angiogenesis by bonemarrow cell transplantationmay contribute to improved ischemic myocardial function," European Journal of Cardio-Thoracic Surgery, vol. 25, no. 2, pp. 188-195, 2004.
58. A. Y. Sheikh, S.-A. Lin, F. Cao et al., "Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium," Stem Cells, vol. 25, no. 10, pp. 2677-2684, 2007.
59. B. E. Strauer, M. Brehm, T. Zeus et al., "Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction," Deutsche Medizinische Wochenschrift, vol. 126, no. 34-35, pp. 932-938, 2001.
60. T. Dill, V. Schachinger, A. Rolf et al., "Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIRAMI) cardiacmagnetic resonance imaging substudy," American Heart Journal, vol. 157, no. 3, pp. 541-547, 2009.
61. J. S. Mills and S. V. Rao, "REPAIR-AMI: stem cells for acute myocardial infarction," Future Cardiology, vol. 3, no. 2, pp. 137-140, 2007.
62. V. Schachinger, S. Erbs, A. Elsasser et al., "Improved clinical outcome after intracoronary administration of bone-marrowderived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial," European Heart Journal, vol. 27, no. 23, pp. 2775-2783, 2006.
63. V. Jeevanantham, M. Butler, A. Saad, A. Abdel-Latif, E. K. Zuba-Surma, and B. Dawn, "Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis," Circulation, vol. 126, no. 5, pp. 551-568, 2012.
64. K. Sadat, S. Ather, W. Aljaroudi, J. Heo, A. E. Iskandrian, and F. G. Hage, "The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion," Journal of Nuclear Cardiology, vol. 21, no. 2, pp. 351-367, 2014.
65. R. de Jong, J. H. Houtgraaf, S. Samiei, E. Boersma, and H. J. Duckers, "Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials," Circulation: Cardiovascular Interventions, vol. 7, no. 2, pp. 156-167, 2014.
66. M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for CellularTherapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
67. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells," Science, vol. 284, no. 5411, pp. 143-147, 1999.
68. X.-J. Wang and Q.-P. Li, "The roles of mesenchymal stem cells (MSCs) therapy in ischemic heart diseases," Biochemical and Biophysical Research Communications, vol. 359, no. 2, pp. 189-193, 2007.
69. J. M. Ryan, F. P. Barry, J. M. Murphy, and B. P. Mahon, "Mesenchymal stem cells avoid allogeneic rejection," Journal of Inflammation, vol. 2, article 8, 2005.
70. Q. Yu, Q. Li, R. Na et al., "Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy," Molecular and Cellular Biochemistry, vol. 387, no. 1-2, pp. 279-285, 2014.
71. S. L. Chen, W. W. Fang, J. Qian et al., "Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction," Chinese Medical Journal, vol. 117, no. 10, pp. 1443-1448, 2004.
72. J. M. Hare, J. H. Traverse, T. D. Henry et al., "A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction," Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277-2286, 2009.
73. X. Wang, W. C. Xi, and F. Wang, "The beneficial effects of intracoronary autologous bone marrow stem cell transfer as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction," Biotechnology Letters, vol. 36, no. 11, pp. 2163-2168, 2014.
74. S. A. Fisher, C. Doree, S. J. Brunskill, A. Mathur, and E. Martin-Rendon, "Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis," PLoS ONE, vol. 8, no. 6, Article ID e64669, 2013.
75. A. N. Nowbar, M. Mielewczik, M. Karavassilis et al., "Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis," The British Medical Journal, vol. 348, Article ID g2688, 2014.
76. S. A. Fisher, S. J. Brunskill, C. Doree, A. Mathur, D. P. Taggart, and E. Martin-Rendon, "Stemcell therapy for chronic ischaemic heart disease and congestive heart failure," Cochrane Database of Systematic Reviews, vol. 4, Article ID CD007888, 2014.
77. J. J. Minguell and A. Erices, "Mesenchymal stem cells and the treatment of cardiac disease," Experimental Biology and Medicine, vol. 231, no. 1, pp. 39-49, 2006.
78. J. D. Dowell, M. Rubart, K. B. S. Pasumarthi, M. H. Soonpaa, and L. J. Field, "Myocyte and myogenic stem cell transplantation in the heart," Cardiovascular Research, vol. 58, no. 2, pp. 336-350, 2003.
79. T. Nomura, E. Ashihara, K. Tateishi et al., "Skeletal myospherederived progenitor cell transplantation promotes neovascularization in delta-sarcoglycan knockdown cardiomyopathy," Biochemical and Biophysical Research Communications, vol. 352, no. 3, pp. 668-674, 2007.
80. N. Dib, J. Dinsmore, Z. Lababidi et al., "One-year follow-up of feasibility and safety of the first U. S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study)," JACC: Cardiovascular Interventions, vol. 2, no. 1, pp. 9-16, 2009.
81. N. Dib, P. McCarthy, A. Campbell et al., "Feasibility andsafetyof autologous myoblast transplantation in patients with ischemic cardiomyopathy," Cell Transplantation, vol. 14, no. 1, pp. 11-19, 2005.
82. H. Ince, M. Petzsch, T. C. Rehders, S. Kische, T. Chatterjee, and C. A. Nienaber, "Percutaneous transplantation of autologous myoblasts in ischemic cardiomyopathy," Herz, vol. 30, no. 3, pp. 223-231, 2005.
83. P. Menasche, A. A. Hagege, J.-T. Vilquin et al., "Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction," Journal of the American College of Cardiology, vol. 41, no. 7, pp. 1078-1083, 2003.
84. C. E. Veltman, O. I. I. Soliman, M. L. Geleijnse et al., "Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy," European Heart Journal, vol. 29, no. 11, pp. 1386-1396, 2008.
85. J. Wang, S. Zhang, B. Rabinovich et al., "Human CD34+ cells in experimentalmyocardial infarction: long-termsurvival, sustained functional improvement, and mechanism of action," Circulation Research, vol. 106, no. 12, pp. 1904-1911, 2010.
86. E. C. Perin and J. T. Willerson, "CD34+ autologous human stem cells in treating refractory angina," Circulation Research, vol. 109, no. 4, pp. 351-352, 2011.
87. T. J. Povsic, C. Junge, A. Nada et al., "A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the renew study," American Heart Journal, vol. 165, no. 6, pp. 854. e2-861. e2, 2013.
88. A. Manginas, E. Goussetis, M. Koutelou et al., "Pilot study to evaluate the safety and feasibility of intracoronary CD133+ and CD133- CD34+ cell therapy in patients with nonviable anteriormyocardial infarction," Catheterization and Cardiovascular Interventions, vol. 69, no. 6, pp. 773-781, 2007.
89. H. Ahmadi, H. Baharvand, S. K. Ashtiani et al., "Safety analysis and improved cardiac function following local autologous transplantation of CD133+ enriched bone marrow cells after myocardial infarction," Current Neurovascular Research, vol. 4, no. 3, pp. 153-160, 2007.
90. A. Kurtz, "Mesenchymal stem cell delivery routes and fate," International Journal of Stem Cells, vol. 1, no. 1, pp. 1-7, 2008.
91. A. W. Heldman and J. M. Hare, "Cell therapy for myocardial infarction: special delivery," Journal of Molecular and Cellular Cardiology, vol. 44, no. 3, pp. 473-476, 2008.
92. J. H. Loughran, J. B. Elmore, M. Waqar, A. R. Chugh, and R. Bolli, "Cardiac stem cells in patients with ischemic cardiomyopathy: discovery, translation, and clinical investigation," Current Atherosclerosis Reports, vol. 14, no. 5, pp. 491-503, 2012.
93. T. I. G. van der Spoel, S. J. Jansen of Lorkeers, P. Agostoni et al., "Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease," Cardiovascular Research, vol. 91, no. 4, pp. 649-658, 2011.
94. R. T. van Beem, A. Hirsch, I. M. Lommerse et al., "Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction," EuroIntervention, vol. 4, no. 1, pp. 133-138, 2008.
95. F. H. Seeger, T. Tonn, N. Krzossok, A. M. Zeiher, and S. Dimmeler, "Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction," European Heart Journal, vol. 28, no. 6, pp. 766-772, 2007.
96. B. Assmus, T. Tonn, F. H. Seeger et al., "Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy," Journal of theAmerican College of Cardiology, vol. 55, no. 13, pp. 1385-1394, 2010.
97. P. J. Hanley, Z. Mei, A. G. Durett et al., "Efficientmanufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System," Cytotherapy, vol. 16, no. 8, pp. 1048-1058, 2014.
98. J. H. Traverse, T. D. Henry, C. J. Pepine et al., "Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial," The Journal of the American Medical Association, vol. 308, no. 22, pp. 2380-2389, 2012.
99. S. Zhang, A. Sun, D. Xu et al., "Impact of timing on efficacy and safetyof intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials," Clinical Cardiology, vol. 32, no. 8, pp. 458-466, 2009.
100. A. Blatt, S. Minha, G. Moravsky, Z. Vered, and R. Krakover, "Intracoronary administration of autologous bone marrow mononuclear cells in patients with chronic ischemic symptomatic cardiomyopathy: 5 years follow-up," Israel Medical Association Journal, vol. 12, no. 12, pp. 738-741, 2010.
101. K. Cheng, K. Malliaras, R. R. Smith et al., "Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair," JACC: Heart Failure, vol. 2, no. 1, pp. 49-61, 2014.
102. L. N. Maslov, Y. K. Podoksenov, A. G. Portnichenko, and A. V. Naumova, "Hypoxic preconditioning of stem cells as a new approach to increase the efficacy of cell therapy for myocardial infarction," Vestnik Rossiiskoi AkademiiMeditsinskikh Nauk, no. 12, pp. 16-25, 2013.
103. H.-H. Lu, Y.-F. Li, Z.-Q. Sheng, and Y. Wang, "Preconditioning of stem cells for the treatment ofmyocardial infarction," Chinese Medical Journal, vol. 125, no. 2, pp. 378-384, 2012.
104. X. Hu, S. P. Yu, J. L. Fraser et al., "Transplantation of hypoxiapreconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis," Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 4, pp. 799-808, 2008.
105. B. Assmus, D. H. Walter, F. H. Seeger et al., "Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial," The Journal of the AmericanMedical Association, vol. 309, no. 15, pp. 1622-1631, 2013.
106. J. L. Herrmann, Y. Wang, A. M. Abarbanell, B. R. Weil, J. Tan, and D. R. Meldrum, "Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection," Shock, vol. 33, no. 1, pp. 24-30, 2010.
107. Y. Luo, Y. Wang, J. A. Poynter et al., "Pretreating mesenchymal stem cells with interleukin-1β and transforming growth factor-β synergistically increases vascular endothelial growth factor production and improves mesenchymal stem cell-mediated myocardial protection after acute ischemia," Surgery, vol. 151, no. 3, pp. 353-363, 2012.
108. N. Takehara, Y. Tsutsumi, K. Tateishi et al., "Controlled delivery of basic fibroblast growth factor promotes human cardiospherederived cell engraftment to enhance cardiac repair for chronic myocardial infarction," Journal of the American College of Cardiology, vol. 52, no. 23, pp. 1858-1865, 2008.
109. J. Chen, A. R. Baydoun, R. Xu et al., "Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis," Stem Cells, vol. 26, no. 1, pp. 135-145, 2008.
110. X. Liu, J. Hou, L. Shi et al., "Lysophosphatidic acid protects mesenchymal stem cells against ischemia-induced apoptosis in vivo," Stem Cells and Development, vol. 18, no. 7, pp. 947-953, 2009.
111. X. Y. Wang, X. S. Fan, L. Cai, S. Liu, X. F. Cong, and X. Chen, "Lysophosphatidic acid rescues bone mesenchymal stem cells from hydrogen peroxide-induced apoptosis," Apoptosis, vol. 20, no. 3, pp. 273-284, 2015.
112. Q. Zhang, H. Wang, Y. J. Yang et al., "Atorvastatin treatment improves the effects of mesenchymal stem cell transplantation on acute myocardial infarction: the role of the RhoA/ROCK/ERK pathway," International Journal of Cardiology, vol. 176, no. 3, pp. 670-679, 2014.
113. J. S. Park, S. Suryaprakash, Y. H. Lao, and K. W. Leong, "Engineering mesenchymal stem cells for regenerative medicine and drug delivery," Methods, 2015.
114. P. T. Yin, E. Han, and K. B. Lee, "Engineering stem cells for biomedical applications," Advanced Healthcare Materials, 2015.
115. A. E. Mayfield, E. L. Tilokee, N. Latham et al., "The effect of encapsulation of cardiac stem cells within matrix-enriched hydrogel capsules on cell survival, post-ischemic cell retention and cardiac function," Biomaterials, vol. 35, no. 1, pp. 133-142, 2014.
116. E. G. Schmuck, J. D. Mulligan, R. L. Ertel et al., "Cardiac fibroblast-derived 3D extracellular matrix seeded with mesenchymal stem cells as a novel device to transfer cells to the ischemic myocardium," Cardiovascular Engineering and Technology, vol. 5, no. 1, pp. 119-131, 2014.
117. R. Santhakumar, P. Vidyasekar, and R. S. Verma, "Cardiogel: a nano-matrix scaffold with potential application in cardiac regeneration using mesenchymal stem cells," PLoS ONE, vol. 9, no. 12, Article ID e114697, 2014.
118. Y. Miyahara, N. Nagaya, M. Kataoka et al., "Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction," Nature Medicine, vol. 12, no. 4, pp. 459-465, 2006.
119. S. Miyagawa, G. Matsumiya, T. Funatsu et al., "Combined autologous cellular cardiomyoplasty using skeletal myoblasts and bone marrow cells for human ischemic cardiomyopathy with left ventricular assist system implantation: report of a case," Surgery Today, vol. 39, no. 2, pp. 133-136, 2009.
120. A. R. Williams, K. E. Hatzistergos, B. Addicott et al., "Enhanced effect of combining human cardiac stemcells and bonemarrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction," Circulation, vol. 127, no. 2, pp. 213-223, 2013.